ClinicalTrials.gg
RecruitingNCT06547515BONUSUpdated Jun 10, 2025

Bone and Muscle Health Following Sleeve Gastrectomy in Men, Premenopausal and Postmenopausal Women

An observational study in Bariatric Surgery, Bone Health and Severe Obesity, sponsored by CHU de Quebec-Universite Laval. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-10.

Sponsored by CHU de Quebec-Universite Laval · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started Sep 2022; still recruiting 4 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
156
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Obesity, Morbid with a site in Canada — 7 open to participants now, 10 under way, none of them phase 3. Obesity, Morbid · Canada.

Planned enrollment
4th of 10
156 · median 145
Started
2022
with 1 other
Observational
10 of 32
3 open now
Registered
29th of 32
by date
Lead sponsor
2 of 32
CHU de Quebec-Universite Laval

Among the 32 studies in Obesity, Morbid with a site in Canada, this one is the 4th largest by planned enrollment of the 10 observational ones that give a count, is one of 2 that started in 2022, is one of 10 observational ones, and was the 29th registered.

Obesity, Morbid

941 studies on the registry are indexed under Obesity, Morbid; 162 are open to participants now.

Browse Obesity, Morbid studies →

Open to participants now

7 of the 32 studies in Obesity, Morbid with a site in Canada are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 109 Obesity, Morbid studies recruiting now, 21 (19%) set no upper age limit and 83 (76%) stop at 75 or younger; 8 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Obesity, Morbid with a site in Canada, or all of them as a file.
02

Study summary

Background: Bariatric surgery is gaining in popularity. While it's health benefits are undisputed, the older malabsorptive bariatric procedures (Roux-in-Y gastric bypass - RYGB and biliopancreatic diversion - BPD) are associated with an increased risk of fractures and falls as early as 3-5 years after surgery. Sleeve gastrectomy - SG is now the most performed bariatric procedure. Although SG does not cause malabsorption, it is predicted to result in bone and muscle loss via weight loss and weight loss-independent mechanisms. Primary aim: to compare the changes in spine volumetric bone mineral density (vBMD) by quantitative computed tomography (QCT) and muscle mass at mid-femur by computed tomography (CT) at 3 years in the 3 groups of: 1) men; 2) premenopausal women; 3) postmenopausal women after SG versus their respective non-surgical peers who did not undergo SG in the 3-year period following recruitment. Secondary aims: to compare the changes in vBMD by QCT at skeletal sites other than the spine and in areal bone mineral density (aBMD) by dual-energy X-ray absorptiometry (DXA), whole-body muscle mass by DXA, muscle quality by CT at mid-femur and muscle strength as well as in selected physical performance and capacity tests shown to predict falls and fractures between 0-1 and 1-3 years after SG in the same 3 groups after SG vs. in the respective non-surgical groups.

03

Conditions studied

  • Bariatric Surgery
  • Bone Health
  • Severe Obesity
  • Muscle Health

Browse trials for

Keywords

  • bariatric surgery
  • Bone health
  • Severe Obesity
  • Muscle Health
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

This is a multicentre, prospective and observational study comprising a SG bariatric group undergoing SG (n=117) comprising an equal number of men, premenopausal and postmenopausal women (n=39/group) meeting the inclusion/exclusion criteria, and assessed before, and at one and 3 years after SG. An obese non-surgical group (n=39; 13 men, premenopausal and postmenopausal women) meeting the criteria for SG but who will not undergo surgery during the 3-year period following recruitment will be assessed using the same tests and at the same timepoints.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women aged >18 years;
  • Awaiting SG for the bariatric group or meeting the criteria for SG but not undergoing surgery for the non-surgical group.
  • Menopause: defined as the absence of menses for a year and a serum follicular-stimulating hormone (FSH) >40 UI/L.
  • Women taking oral pills or hormone replacement therapy
  • Patients with type 2 diabetes.

Exclusion criteria

Exclusion Criteria:

  • Type 1 diabetes;
  • Disease (e.g., uncontrolled thyroid disease, Malabsorptive or overt inflammatory disorder)
  • Metabolic bone disease other than osteoporosis or type 2 diabetes,
  • \<30 ml/min) or medication (e.g., , anti-epileptic drugs, osteoporosis therapy, thiazolidinediones) affecting bone metabolism;
  • Weight >204 kg (DXA weight limit) or >60 kg/m2 (upper limit to allow for QCT examination);
  • Current or planned pregnancy during follow-up; breast-feeding.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
156 participants (estimated)
Target follow-up
36 Months
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Sleeve gastrectomy - Men

    n = 39 men with obesity undergoing sleeve gastrectomy

    Procedure: Bariatric surgery

  • Sleeve gastrectomy - Premenopausal women

    n = 39 premenopausal women with obesity undergoing sleeve gastrectomy

    Procedure: Bariatric surgery

  • Sleeve gastrectomy - Postmenopausal women

    n = 39 postmenopausal women with obesity undergoing sleeve gastrectomy

    Procedure: Bariatric surgery

  • Obese non-surgical group

    n = 39 (13 men, 13 premenopausal and 13 postmenopausal women) obese non-surgical individuals

Interventions

  • ProcedureBariatric surgery

    Sleeve gastrectomy

06

What researchers measure

Primary outcomes

  1. Change in vBMD at the spine (L2-L3) and proximal femur

    assessed by QCT

    Time frame: before, 1 year after and 3 years after bariatric surgery

  2. Change in muscle mass at mid-femur

    determined by measuring cross-sectional area at mid-femur (CT)

    Time frame: before, 1 year after and 3 years after bariatric surgery

Secondary outcomes

  1. Change in vBMD at skeletal sites other than the spine

    assessed by QCT

    Time frame: before, 1 year after and 3 years after bariatric surgery

  2. Change in aBMD at skeletal sites

    assessed by DXA

    Time frame: before, 1 year after and 3 years after bariatric surgery

  3. Change in whole body muscle mass

    assessed by DXA

    Time frame: before, 1 year after and 3 years after bariatric surgery

  4. Change in muscle quality at mid-femur

    muscle fat infiltration, using CT attenuation in Hounsfield unit (HU)

    Time frame: before, 1 year after and 3 years after bariatric surgery

  5. Change in muscle strength

    assessed by CT

    Time frame: before, 1 year after and 3 years after bariatric surgery

  6. Change in upper extremity muscle strength

    by hand grip strength

    Time frame: before, 1 year after and 3 years after bariatric surgery

  7. Change in lower extremity muscle strength

    knee extensor strength

    Time frame: before, 1 year after and 3 years after bariatric surgery

  8. Change in muscle mass (muscle cross-sectional area) and function

    by timed up and go test

    Time frame: before, 1 year after and 3 years after bariatric surgery

  9. Change in muscle mass (muscle cross-sectional area) and function

    by 6-minute walk test

    Time frame: before, 1 year after and 3 years after bariatric surgery

Other outcomes

  1. The clinical impact of SG on self-reported falls

    by self-reported questionnaire (yes/No)

    Time frame: before, 1 year after and 3 years after bariatric surgery

  2. The clinical impact of SG on self-reported incidence of vertebral and non-vertebral fractures

    by questionnaire (yes/No and number of fractures, how)

    Time frame: before, 1 year after and 3 years after bariatric surgery

  3. The proportion of participants meeting the recommendations for physical activity

    by international physical activity questionnaire short version (score in MET-min/week), (Min 495 MET-minute/week, Max 1200 MET-minute/week)

    Time frame: before, 1 year after and 3 years after bariatric surgery

  4. The proportion of participants meeting the recommendations for dietary protein intake

    Dietary journal, Calculating macronutrient and micronutrient intake per day 3 web-based 24-h recalls

    Time frame: before, 1 year after and 3 years after bariatric surgery

  5. The proportion of participants meeting the recommendations for calcium and vitamin D intake from diet and supplements

    serum D vitamin (25ODH) in blood sample

    Time frame: before, 1 year after and 3 years after bariatric surgery

  6. The proportion of participants meeting the recommendations for calcium and vitamin D intake from diet and supplements

    Parathyroid hormone (PTH) in blood sample

    Time frame: before, 1 year after and 3 years after bariatric surgery

  7. Changes in C-Telopeptide, amino-terminal propeptide of type 1 procollagen (P1NP), osteocalcin

    assessed by blood sample. unit: micro g/l

    Time frame: before, 1 year after and 3 years after bariatric surgery

  8. Changes in calcium,

    assessed by blood sample. unit: mmol/l

    Time frame: before, 1 year after and 3 years after bariatric surgery

  9. Changes in albumin,

    assessed by blood sample. unit:g/l

    Time frame: before, 1 year after and 3 years after bariatric surgery

  10. Changes in creatinin

    assessed by blood sample. unit: micromol/l

    Time frame: before, 1 year after and 3 years after bariatric surgery

  11. Changes in folliculo-stimulant (FSH)

    assessed by blood sample. unit: UI/l FSH will help categorize hysterectomized women or those with non-menopausal amenorrhea. Premenopause will be defined as menses in the last year.

    Time frame: FSH will be measured at the time of surgery, when women had withdrawn their hormones for 3 months preceding surgery.

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2022 (actual). Primary completion is estimated for Aug 2026, 47 months after the start.

Of 138 non-industry observational studies under Obesity, Morbid, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 132. This study's planned 47 months is close to that.

Counting every sponsor, half of 139 studies reached it within 46 months; a quarter within 16 and three quarters within 132.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2024
First posted
Aug 9, 2024
StartActual
Sep 14, 2022
Primary completionEst.
Aug 15, 2026
CompletionEst.
Aug 15, 2026
Last update
Jun 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06547515
Responsible party
Claudia Gagnon (Principal Investigator, Endocrinologist, Regular Researcher of the Endocrinology-Nephrology Axis, CHU de Quebec-Universite Laval) — Principal investigator
First posted
Aug 9, 2024
Start date
Sep 14, 2022
Primary completion
Aug 15, 2026 (estimated)
Completion
Aug 15, 2026 (estimated)
Last update
Jun 10, 2025

Study contacts

Sandrine Hegg-Deloye, PhD
Contact
sandrine.hegg-deloye@crchudequebec.ulaval.ca
4185254444 ext. 48729
Claudia Gagnon, Dr
principal investigator · CHU de Québec - Université Laval

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion